Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Gains from Investment Securities (2023 - 2025)

Historic Gains from Investment Securities for Contineum Therapeutics (CTNM) over the last 3 years, with Q1 2025 value amounting to $200000.0.

  • Contineum Therapeutics' Gains from Investment Securities fell 3333.33% to $200000.0 in Q1 2025 from the same period last year, while for Sep 2025 it was $6.8 million, marking a year-over-year increase of 6391.61%. This contributed to the annual value of $4.0 million for FY2024, which is 5126.73% up from last year.
  • Contineum Therapeutics' Gains from Investment Securities amounted to $200000.0 in Q1 2025, which was down 3333.33% from $6.6 million recorded in Q4 2024.
  • In the past 5 years, Contineum Therapeutics' Gains from Investment Securities ranged from a high of $6.6 million in Q4 2024 and a low of -$5000.0 during Q1 2023
  • Over the past 3 years, Contineum Therapeutics' median Gains from Investment Securities value was $487000.0 (recorded in 2023), while the average stood at $2.0 million.
  • Per our database at Business Quant, Contineum Therapeutics' Gains from Investment Securities skyrocketed by 610000.0% in 2024 and then tumbled by 3333.33% in 2025.
  • Contineum Therapeutics' Gains from Investment Securities (Quarter) stood at $574000.0 in 2023, then soared by 1042.33% to $6.6 million in 2024, then crashed by 96.95% to $200000.0 in 2025.
  • Its Gains from Investment Securities was $200000.0 in Q1 2025, compared to $6.6 million in Q4 2024 and $4.1 million in Q3 2024.